Simonmed Announces Offering Of Datscan

(MENAFN- PR Newswire) SCOTTSDALE, Ariz., April 24, 2023 /PRNewswire/ -- SimonMed is proud to announce we will offer GE HealthCare's radiopharmaceutical diagnostic tracer, DaTscanTM
(Ioflupane I 123 injection), with DaTQUANTTM
nationally starting immediately in all of our markets.

continue reading

Figure 1 - FDG PET-CT scan in patient with Dementia with Lewy Bodies (DLB). Abnormal hypometabolism within the bilateral occipital lobes highlighted with purple color. (PRNewsfoto/SimonMed Imaging)
Figure 2a - DaTscan image showing symmetrically reduced Ioflupane 123 uptake bilaterally demonstrating an abnormal pattern of DaTscan uptake. (PRNewsfoto/SimonMed Imaging)
Figure 2b - DatQUANT showing symmetric abnormal striatal binding ratios with Z scores of more than 2SD below the mean confirming the visually abnormal DaTscan and consistent with abnormal FDG PET-CT scan diagnosis of DLB. Abnormal striatal binding ratios help confirm the visually abnormal diagnosis. (PRNewsfoto/SimonMed Imaging)

DaTscan was recently approved by the U.S. Food and Drug Administration (FDA) for an expanded label which includes use in patients with suspected Dementia with Lewy Bodies (DLB). The new indication is in addition to its use with single photon emission computed tomography (SPECT) imaging to visualize dopamine transporters (DaT) in the brains of adult patients with suspected Parkinsonian syndromes. With the expanded indication, DaTscan is now available to more patients, including those with suspected DLB, in the U.S.

Approximately one in five patients with dementia suffers from DLB, making it the second most common form of degenerative dementia after Alzheimer's disease1. The clinical signs and symptoms of DLB can be atypical and overlap with other forms of dementia, leading to up to 70% of patients with DLB being misdiagnosed, often as having Alzheimer's disease2. This new indication enables SimonMed clinicians to use DaTscan as part of their diagnostic workup to help differentiate DLB from other forms of dementia. Early and accurate diagnosis of DLB can help ensure specific appropriate treatment and specialized care for patients, while enabling them and their caregivers to more effectively manage the disease and plan for the future3.

John P. Uglietta, MD, Emeritus Medical Director of Neuroradiology at SimonMed Imaging (SMI) said: "SimonMed is the National Leader in imaging patients with movement disorders having done more DaTscans than any other single medical entity in the country. Additionally, SMI was an early adopter of using DaTQUANT as a quantitative objective tool to aid in the visual interpretation of DaTscan to improve accuracy and diagnostic confidence over visual interpretation alone. Today, we are the largest specialty outpatient radiology practice in the US utilizing DaTscan with DaTQUANT and we have standardized our protocol to include DaTQUANT with every DaTscan ordered across all of our National imaging centers. The extensive experience of SimonMed Neuroradiologists interpreting DaTscans and FDG PET-CT scans of the brain significantly improves the confidence level of receiving an accurate diagnosis of Parkinson's related movement disorders and now offering improved accuracy of obtaining a confirmed diagnosis of DLB."

Amanda Hamilton, General Manager, Molecular Imaging of GE HealthCare's U.S Pharmaceutical Diagnostics division said: "We are pleased to support our longstanding customer SimonMed in their efforts to offer broad access to leading-edge diagnostic Neuroimaging options for clinicians and their patients. Our expanded DaTscan label is an example of GE HealthCare's commitment towards advancing the future of Molecular Imaging through research and innovation, by delivering products and solutions that help empower better patient care and outcomes. We look forward to our continued collaboration with SimonMed including potential future clinical studies for new SPECT imaging agents and new PET-CT agents."

About SimonMed Imaging

Headquartered in Scottsdale, Arizona, SimonMed is one of the largest independent outpatient medical imaging providers and physician radiology practices in the United States. SimonMed has 147 sites across 11 states and nearly 200 subspecialty-trained radiologists. SimonMed Imaging offers the full modality of diagnostic scans, including 3T MRI, CT, ultrasound, 3-D mammography, PET/CT, nuclear medicine, DEXA, X-rays, among others. The company uses the newest, most-advanced, diagnostic imaging technologies while maintaining affordability and accessibility. SimonMed is a worldwide leader in the clinical use of AI to improve diagnoses with one of the largest global deployments to enhance early breast cancer detection and in the evaluation of brain disorders. Through its simonONE division, SimonMed is also at the forefront of personalized imaging for the early diagnosis and treatment of disease. For more information, visit .

References:

1 Barker, Warren W et al. "Relative frequencies of Alzheimer disease, Lewy body, vascular and frontotemporal dementia, and hippocampal sclerosis in the State of Florida Brain Bank."
Alzheimer disease and associated disorders
vol. 16,4 (2002): 203-12. doi:10.1097/00002093-200210000-00001

2
Warr et al. Q J Nucl Med Mol Imaging; 2012; 56: 39-54

3
Zweig and Galvin Alzheimer's Research & Therapy 2014, 6.21;

Pr oduct
Indications
and Important
Safety
Information –
DaTscan

P RODUCT
INDICATION
AND USE

DATSCAN is indicated as an adjunct to other diagnostic evaluations for striatal dopamine transporter visualization using single photon emission computed tomography (SPECT) brain imaging in adult patients with:

• suspected Parkinsonian syndromes (PS) or
• suspected dementia with Lewy bodies (DLB).

Important
Safety
Information About
DaTscanTM
(ioflupane
I
123
injection)

CONTRAINDICATIONS

• DaTscan is contraindicated in patients with known serious hypersensitivity to ioflupane I 123.

WA RNINGS
AND
PRECAUTIONS

• Hypersensitivity Reactions: Hypersensitivity reactions, including dyspnea, edema, rash, erythema, and pruritus, have been reported following DATSCAN administration.
• Th yroid Accumulation: DaTscan may contain up to 6% of free iodide (iodine-123). Thyroid uptake of iodine-123 may result in an increased long-term risk for thyroid neoplasia. To decrease thyroid accumulation of iodine-123, block the thyroid gland before administration of DaTscan.

AD V E RSE
REACTIONS

• In clinical trials, headache, nausea, vertigo, dry mouth, or dizziness of mild to moderate severity were reported. In postmarketing experience, hypersensitivity reactions and injection-site pain have been reported

D RUG INTERACTIONS

• Drugs that bind to the dopamine transporter with high affinity may interfere with the DaTscan image. The impact of dopamine agonists and antagonists on DaTscan imaging results has not been established

US E
IN
SPECIFIC
POPULATIONS

• P re gnancy: Radioactive iodine products cross the placenta and can permanently impair

fetal thyroid function. Administration
of a
thyroid blocking agent
is
recommended before
the use
of
DaTscan
in
a pregnant
woman. All radiopharmaceuticals
have
potential to
cause
fetal harm. There
are
no
available
data on
DaTscan
use
in
pregnant
women
to
evaluate
for
a drug- associated
risk
of major
birth
defects, miscarriage
or
adverse
maternal or
fetal outcomes. Advise
pregnant
woman
of the
potential risks
of
fetal exposure
to
radiation
with
the administration
of DaTscan

Pr oduct
Indications
and Important
Safety
Information –
DaTscan

• Lactation: Iodine 123 (I 123), the radionuclide in DaTscan, is present in human milk. There is no information on the effects on breastfed infants or on milk. Advise a lactating woman to interrupt breastfeeding and pump and discard breast milk for at least 6 days after DaTscan administration to minimize radiation exposure to a breastfeeding infant
• Pediatric Use: The safety and efficacy of DaTscan have not been established in pediatric patients
• Geriatric Use: There were no differences in responses between elderly patients and younger patients that would require a dose adjustment observed in the parkinsonian syndrome studies.
• Renal Impairment: DaTscan is excreted by the kidney and patients with severe renal impairment may have increased radiation exposure and altered DaTscan images

O V E RDOSAGE

• The risks of overdose relate predominantly to increased radiation exposure, with the long-term risks for neoplasia. In case of overdosage of radioactivity, frequent urination and defecation should be encouraged to minimize radiation exposure to the patient.

P ROCEDURE
-
Radiation
Safety

• DaTscan emits radiation and must be handled with safety measures to minimize radiation exposure to clinical personnel and patients

P r ior to DaTscan administration, please read
the
full Prescribing Information
for additional
I mportant Safety
Information.

T o report SUSPECTED ADVERSE
REACTIONS,
contact GE Healthcare
at 800
654
0118
(option
2, then
option
1)
or the FDA at 800
FDA 1088
o r .

SOURCE SimonMed Imaging

MENAFN24042023003732001241ID1106082257